Featured
BPC-157, KPV, and TB-500 Win Favorable PCAC Votes
BPC-157, KPV, and TB-500 won favorable PCAC votes, building momentum toward the 503A Bulks List and regulated peptide compounding.
Read the guideBrowse the journal
All articles
Featured
Rebody Journal
BPC-157, KPV, and TB-500 Win Favorable PCAC Votes
BPC-157, KPV, and TB-500 won favorable PCAC votes, building momentum toward the 503A Bulks List and regulated peptide compounding.
Read the guide
Featured
Rebody Journal
16 Million BPC-157 Doses and Seven Complaints: The PCAC Testimony
Dr. Alex Tatem brought data covering more than 16 million BPC-157 doses to PCAC—along with seven complaints and no clear attributable adverse safety signal.
Read the guide
Featured
Rebody Journal
Dr. Alex Tatem’s TB-500 PCAC Testimony: The Full Case
Human thymosin beta-4 trials, nearly 190,000 compounded vials, empty FDA adverse-event searches, and a favorable 8–6–1 PCAC vote.
Read the guide
Featured
Rebody Journal
What Is PCAC? Why the July 2026 Peptide Vote Matters
PCAC put seven peptides and the 503A Bulks List in the national spotlight. Here is what the committee does and why the July 2026 votes matter.
Read the guide
Featured
Rebody Journal
PCAC’s Peptide Votes Put the 503A Bulks List in Focus
BPC-157, KPV, and TB-500 put the 503A Bulks List in the spotlight—and built momentum for peptide compounding through licensed pharmacies.
Read the guide
Featured
Rebody Journal
PCAC Peptides: The Full July 2026 List, Schedule, and Results
The complete July 2026 PCAC peptide list, two-day schedule, favorable BPC-157, KPV and TB-500 results, and official webcast links.
Read the guide
Featured
Rebody Journal
KPV Wins a Favorable PCAC Vote for the 503A Bulks List
KPV won a favorable PCAC recommendation for the 503A Bulks List, joining BPC-157 and TB-500 in a major Day 1 for peptide compounding.
Read the guide
Featured
Rebody Journal
PCAC Live Stream July 24: DSIP, Epitalon, and Semax Votes
The July 24 PCAC livestream begins at 8 a.m. Eastern with emideltide (DSIP), Epitalon, and Semax on the peptide agenda.
Read the guide
Featured
Rebody Journal
Emideltide (DSIP) PCAC Vote: What to Watch on July 24
Emideltide—better known as DSIP—opens the July 24 PCAC peptide slate with separate free-base and acetate questions.
Read the guide
Featured
Rebody Journal
Epitalon PCAC Vote: The Longevity Peptide Heads to 503A Review
Epitalon brings sleep and longevity interest to PCAC Day 2 with separate free-base and acetate votes for the 503A Bulks List.
Read the guide
Featured
Rebody Journal
Semax PCAC Vote: Focus and Cognitive Peptide Takes Center Stage
Semax closes PCAC Day 2 with separate free-base and acetate votes and a spotlight on neurological and cognitive peptide interest.
Read the guide
Featured
Rebody Journal
PCAC Day 2 Preview: DSIP, Epitalon, and Semax
PCAC Day 2 moves from sleep to longevity to cognition with DSIP, Epitalon, and Semax following a major opening day.
Read the guide
Featured
Rebody Journal
What Favorable PCAC Votes Could Mean for DSIP, Epitalon, and Semax
Favorable PCAC votes would move DSIP, Epitalon, and Semax toward the 503A Bulks List and regulated peptide compounding.
Read the guide
Featured
Rebody Journal
Three Peptides to Watch at Tomorrow’s PCAC Meeting
DSIP brings sleep. Epitalon brings longevity. Semax brings cognition. All three reach PCAC tomorrow.
Read the guide
Rebody Journal
How to Start TRT Online in 2026: Step-by-Step Guide
Start TRT online in 2026: fasting labs, clinician review, and a prescription that ships. Compare injections vs enclomiphene before you pick a protocol.
Read the guide
Rebody Journal
Signs of Low Testosterone: How to Know in 2026
Signs of low testosterone explained: symptoms, the 300 ng/dL threshold, testing mistakes to avoid, and how enclomiphene compares to TRT in 2026.
Read the guide
Rebody Journal
Online Testosterone Therapy Clinic: 2026 Buy Verdict
Compare online testosterone therapy clinic models for 2026 — async telehealth with home lab kits wins, compounding-only sellers and queues lose. See the verdict.
Read the guide
Rebody Journal
HCG Therapy for TRT Fertility: Best Options in 2026
HCG plus TRT combination protocols lead for fertility preservation in 2026 — compare HCG, enclomiphene, and gonadorelin doses, costs, and verdicts.
Read the guide
Rebody Journal
At-Home Testosterone Test Before TRT: 2026 Guide
At-home testosterone test kits compared for 2026: venous draw wins on accuracy, saliva testing gets skipped, and one reading isn't enough for a TRT diagnosis.
Read the guide
Rebody Journal
Best Testosterone Therapy Online for Low T (2026)
Ranked comparison of testosterone therapy online options in 2026 — TRT injections, enclomiphene, and sermorelin, with clear Buy/Consider/Skip verdicts.
Read the guide
Rebody Journal
TRT Weight Loss 2026: What Works, What Doesn't
TRT weight loss verdicts for 2026: when TRT alone works, when to add enclomiphene or sermorelin, and when to skip TRT entirely based on your labs.
Read the guide
Rebody Journal
Growth Hormone Therapy for Adults: What to Buy in 2026
Growth hormone therapy for adults with GH deficiency: sermorelin injections vs nasal spray compared, plus what to skip, with clear verdicts for 2026.
Read the guide
Rebody Journal
Online TRT for Men Over 40: 2026 Buying Guide
Online TRT for men over 40 compared: testosterone injections vs enclomiphene vs sermorelin add-ons, with clear verdicts for 2026.
Read the guide
Rebody Journal
Testosterone Therapy for Low Libido: 2026 Verdict
Testosterone therapy for low libido and fatigue, ranked: injections, enclomiphene, sermorelin compared by fertility impact and verdict for 2026.
Read the guide